CHRS FY 2024 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$267M+3.8% YoY

Gross Profit

$149M56.0% margin

Operating Income

-$112M-41.8% margin

Net Income

$29M10.7% margin

EPS (Diluted)

$0.25

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$449M

Total Liabilities

$581M

Stockholders' Equity

-$132M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$267M	$257M	+3.8%
Gross Profit	$149M	$98M	+52.1%
Operating Income	-$112M	-$203M	+45.0%
Net Income	$29M	-$238M	+112.0%